Narsipur N, Bulla S, Yoo C, Do B, Tran K, Gu D, Zhong L, Wilson L. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021;27(12):1691-1702. Google ScholarPubMedLog in or register to post comments